SSRI CHINA news

SSRI China participated in the 12th China Pharmaceutical Decision Science Summit and the 2024 annual meeting of China Pharmaceutical Market Research Association (CphMRA) hosted by the China Market Research Association (CMRA) from May 29 to 31 in Nanchang, the capital of Jiangxi province. This year’s summit attracted a total of 230 on-site guests and over 2,300 online guests, setting a historical high. The theme of this summit is “Artificial Intelligence + Medicine -- Digital Productivity” and the aim is to explore the comprehensive application of new big models and big data in the pharmaceutical industry, promote the digital industrialization and digitization of the pharmaceutical industry, and to promote the deep integration of digital technology and the pharmaceutical industry.

At the conference, Jane Zhang from SSRI China delivered a keynote speech entitled “New trends in the three major pharmaceutical markets of US, China and Japan” based on a large-scale physician survey database, PatientsMap. The presentation focused on a comparative analysis of these three countries in terms of the cancer market, rare disease market and the demands for new drugs.

Staffs from SSRI CHINA and SSRI group company HIMA attended the 11th CphMRA (China Pharmaceutical Market Research Association) conference held during May 17th-19th in Wuhan. The theme of this year’s conference is “Interaction of Digital & Real World and Intelligent Creates the Future”. Around 200 people from pharmaceutical companies, market research companies and pharmaceutical big data and business intelligence analysis companies attended the conference. The summit discusses the development of the pharmaceutical industry in comprehensive economic recovery and deepening reform, the integration of digital economy and traditional economy, changes in the policy market environment in the pharmaceutical field, the comprehensive rise of county/community/new retail/smart hospitals/pharmaceutical e-commerce, the comprehensive embrace of the Internet and digitization by doctors and patients, the comprehensive application of big data and artificial intelligence, and the innovation of patient-centered full course management Digital transformation and other aspects of the industry, including data, analysis, insight, change needs of intelligent applications and innovative solutions.

Jane Zhang, from SSRI China, did a presentation on “Appropriate Allocation of Multiple Marketing Methods Such as Pharmaceutical Sales Representatives” based on a large scale physician survey data (PatientsMap), and shared about trends in overall market size changes and resource allocation, demand for new drugs and research and development strategies, sales representative visits, and doctors' trust in pharmaceutical manufacturers. This presentation was awarded Industry Development Contribution Award by the CphMRA.

During tea break, colleagues in the industry exchanged ideas at SSRI China booth.